Synthesis, in vitro evaluation, and computational simulations studies of 1,2,3-triazole analogues as DPP-4 inhibitors

Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus

(2018) Ning Li et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Novel 1,2,3-Triazole Analogs of Sitagliptin as DPP4 Inhibitors

(2016) Shankariah Gundeti et al.   BULLETIN OF THE KOREAN CHEMICAL SOCIETY

Novel tetrahydropyran analogs as dipeptidyl peptidase IV inhibitors: Profile of clinical candidate (2R,3S,5R)-2-(2,5-difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-amine (23)

(2013) Tesfaye Biftu et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Discovery of DA-1229: A potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

(2011) Heung Jae Kim et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Recent patents of dipeptidyl peptidase IV inhibitors

(2011) Laura Mendieta et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors

(2009) E.J. Verspohl   PHARMACOLOGY & THERAPEUTICS